计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N126132-5mg |
5mg |
现货 ![]() |
| |
| N126132-25mg |
25mg |
现货 ![]() |
| |
| N126132-100mg |
100mg |
现货 ![]() |
| |
| N126132-250mg |
250mg |
现货 ![]() |
| |
| N126132-1g |
1g |
现货 ![]() |
|
| 别名 | 来那替尼 | (2E)-N-[4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基]-4-(二甲氨基)-2-丁烯酰胺 |
|---|---|
| 英文别名 | EC 244-343-6 | N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide | CHEBI:61397 | N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide | |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Neratinib (HKI-272) |
| 生化机理 | 奈拉替尼是表皮生长因子受体(EGFR)和神经(HER2)的强效选择性抑制剂(IC50 = 92 nM 和 59 nM),它能阻止这些蛋白被各自的激酶磷酸化。奈拉替尼对 A431、3T3 和 MDA-MB-435 等多种癌细胞株具有活性。奈拉替尼是c-Src和Flk-1的抑制剂。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 受体蛋白-酪氨酸激酶 erbB-4 抑制剂 |
| 产品介绍 |
Neratinib (HKI-272)是一种高度选择性的HER2和EGFR抑制剂,IC50分别为59 nM和92 nM;微弱抑制KDR和Src,对Akt,CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf和c-Met没有显著的抑制作用。Phase 3。A potent and selective inhibitor of EGFR and HER2 Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3. |
| 纯度 | ≥99% |
| ALogP | 4.9 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide |
| INCHI | 1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+ |
| InChi Key | JWNPDZNEKVCWMY-VQHVLOKHSA-N |
| Smiles | CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C |
| Isomeric SMILES | CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C |
| 分子量 | 557.04 |
| Reaxy-Rn | 23404860 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23404860&ln= |
| 溶解性 | Soluble in DMSO (2 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
|---|---|
| 敏感性 | 对热敏感 |
| 分子量 | 557.000 g/mol |
| XLogP3 | 4.900 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 11 |
| 精确质量Exact Mass | 556.199 Da |
| 单同位素质量Monoisotopic Mass | 556.199 Da |
| 拓扑极表面积Topological Polar Surface Area | 112.000 Ų |
| 重原子数Heavy Atom Count | 40 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 881.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E et al.. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.. Cancer Res, 64 (11): (3958-65). [PMID:15173008] |
| 2. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M et al.. (2016) Adaptive Randomization of Neratinib in Early Breast Cancer.. N Engl J Med, 375 (1): (11-22). [PMID:27406346] |